Portnoy Law Firm Announces Class Action Against Medpace Holdings

Lawsuit alleges Medpace misled investors about its book-to-bill ratio and business outlook

Apr. 10, 2026 at 6:59pm

Got story updates? Submit your updates here. ›

A clean, modern studio photograph featuring a stack of legal documents, a pen, and a calculator arranged on a plain white background, conceptually representing the abstract financial and legal issues at the heart of a corporate lawsuit.A minimalist still life captures the legal complexities behind a class action lawsuit against a pharmaceutical services firm.Los Angeles Today

The Portnoy Law Firm has filed a class action lawsuit against Medpace Holdings, Inc. on behalf of investors who bought the company's securities between April 22, 2025 and February 9, 2026. The lawsuit alleges that Medpace, a clinical contract research organization, made false and misleading statements about its projected book-to-bill ratio and the impact of cancellations on its business.

Why it matters

The lawsuit highlights concerns about transparency and accountability in the pharmaceutical and biotech services industry, where accurate financial reporting and forecasting are crucial for investors. The case could have broader implications for how CROs disclose information that impacts their financial performance.

The details

The Medpace class action lawsuit alleges the company consistently overstated its projected book-to-bill ratio for Q4 2025, failed to disclose the impact of cancellations, and reassured investors about its business outlook despite these issues. On February 9, 2026, Medpace reported a Q4 2025 book-to-bill ratio of 1.04, well below its guidance, causing the stock price to drop nearly 16%.

  • The class period covers April 22, 2025 to February 9, 2026.
  • Investors have until June 8, 2026 to file a lead plaintiff motion.

The players

Portnoy Law Firm

A law firm representing investors in pursuing claims caused by corporate wrongdoing. The firm's founding partner has recovered over $5.5 billion for aggrieved investors.

Medpace Holdings, Inc.

A clinical contract research organization (CRO) focused on providing outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries.

Got photos? Submit your photos here. ›

What they’re saying

“Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: lesley@portnoylaw.com, to discuss their legal rights, or join the case via https://portnoylaw.com/medpace-holdings-inc.”

— Lesley F. Portnoy, Attorney

What’s next

The judge will decide on June 8, 2026 whether to allow the case to proceed as a class action lawsuit.

The takeaway

This case highlights the importance of accurate financial reporting and transparency in the pharmaceutical services industry, where investors rely on CROs to provide reliable information about their business performance.